Ignite Creation Date:
2025-12-24 @ 11:14 PM
Ignite Modification Date:
2025-12-25 @ 8:49 PM
Study NCT ID:
NCT05870969
Status:
RECRUITING
Last Update Posted:
2023-05-23
First Post:
2023-05-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006528', 'term': 'Carcinoma, Hepatocellular'}, {'id': 'D019698', 'term': 'Hepatitis C, Chronic'}, {'id': 'D019694', 'term': 'Hepatitis B, Chronic'}, {'id': 'D008103', 'term': 'Liver Cirrhosis'}, {'id': 'D065626', 'term': 'Non-alcoholic Fatty Liver Disease'}], 'ancestors': [{'id': 'D000230', 'term': 'Adenocarcinoma'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008113', 'term': 'Liver Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D006526', 'term': 'Hepatitis C'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018178', 'term': 'Flaviviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D006521', 'term': 'Hepatitis, Chronic'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D006509', 'term': 'Hepatitis B'}, {'id': 'D018347', 'term': 'Hepadnaviridae Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D005355', 'term': 'Fibrosis'}, {'id': 'D005234', 'term': 'Fatty Liver'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 20000}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-03-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-05', 'completionDateStruct': {'date': '2028-03', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-05-13', 'studyFirstSubmitDate': '2023-05-13', 'studyFirstSubmitQcDate': '2023-05-13', 'lastUpdatePostDateStruct': {'date': '2023-05-23', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-05-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'The number of patients first diagnosed with liver cancer and the annual incidence rate', 'timeFrame': 'Four years collectively after the study started'}, {'measure': 'The number of patients first diagnosed with liver cancer and the annual incidence rate within each risk category', 'timeFrame': 'Four years collectively after the study started'}, {'measure': 'The distribution of the CNLC staging of patients diagnosed as liver cancer first from the start of the study to the completion of follow-up', 'timeFrame': 'Four years collectively after the study started'}, {'measure': 'The 3-year cumulative incidence of liver cancer in each disease subgroup', 'timeFrame': 'Follow up up to 3 years', 'description': 'The disease types include but are not limited to hepatitis B, hepatitis C, cirrhosis, MAFLD'}, {'measure': 'Early diagnosis rate of HCC in each disease subgroup', 'timeFrame': 'Four years collectively after the study started', 'description': 'The disease types include but are not limited to hepatitis B, hepatitis C, cirrhosis, MAFLD; early diagnosis of HCC is defined as the patient with stage CNLC Ia, Ib and IIa'}, {'measure': 'The compliance rate of each risk group defined at the initial risk stratification', 'timeFrame': 'Four years collectively after the study started', 'description': 'The compliance rates for subjects with very high-risk, high-risk, medium-risk, and low-risk; the compliance rate is defined the same as above'}], 'primaryOutcomes': [{'measure': 'Early diagnosis rate of HCC patients', 'timeFrame': 'Follow up up to three years for HCC occurance.', 'description': 'The proportion of patients who are first diagnosed with HCC at early stage to all the patients diagnosed as liver cancer in the study, from the start of the study to the completion of follow-up. Early diagnosis is defined as the patient with stage CNLC Ia, Ib and IIa.'}], 'secondaryOutcomes': [{'measure': 'Proportion of subjects with regular follow-up', 'timeFrame': 'Four years collectively after the study started', 'description': 'Regular follow-up is defined as the average difference between the actual treatment time and the theoretical treatment time equal or less than 1/3\n\n* Actual visit interval: actual visit date - previous visit date ② Theoretical visit interval: theoretical visit date (the date that physician advise to return to hospital for visit) - previous visit date ③ Follow-up compliance = (②-①)/② ④ Patient with regular follow-up is defined as the patient whose mean follow-up compliance is equal to, or less than 1/3\n\n * The compliance of the study is defined as the proportion of subjects with regular follow-up to all subjects in the study.'}, {'measure': 'The distribution of risk stratification of liver cancer in subjects at initial screening', 'timeFrame': 'Initial screening after enrollment', 'description': 'The proportion of very high-risk, high-risk, medium-risk, and low-risk subjects to the whole subject population'}, {'measure': 'The distribution of risk stratification of liver cancer in subjects at the last follow-up visit or at the time of diagnosis of liver cancer', 'timeFrame': 'Last follow-up visit or at the time of diagnosis of liver cancer up to three years of follow-up', 'description': 'The proportion of very high-risk, high-risk, medium-risk and low-risk subjects to the whole subject population'}, {'measure': 'Pooled 3-year cumulative incidence of liver cancer', 'timeFrame': 'Follow up up to 3 years'}, {'measure': 'The early diagnosis rate of liver cancer in each subject category according to the risk stratification at initial screening', 'timeFrame': 'Initial screening after enrollment', 'description': 'The early diagnosis rate of liver cancer of subjects with very high-risk, high-risk, medium-risk, and low-risk at initial screening, respectively'}, {'measure': 'The 3-year cumulative incidence of liver cancer in each subject category according to the risk stratification at the time of initial diagnosis', 'timeFrame': 'Four years collectively after the study started', 'description': 'The 3-year cumulative incidence of liver cancer for subjects with very high-risk, high-risk, medium-risk, and low-risk, respectively'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Carcinoma, Hepatocellular', 'Hepatitis C, Chronic', 'Hepatitis B, Chronic', 'Cirrhosis, Liver', 'Non-Alcoholic Fatty Liver Disease']}, 'descriptionModule': {'briefSummary': 'The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'This study mainly includes the following risk groups of liver cancer: patients with chronic hepatitis B, patients with hepatitis C, patients with liver cirrhosis, patients with metabolic dysfunction-associated fatty liver disease (MAFLD) with a liver fibrosis index F3 or above, MAFLD patients combined with abnormal glucose metabolism, and people with a family history of liver cancer in their first-degree biological relatives.', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Voluntary participation in the clinical study; fully informed about the study and signed informed consent, willing to follow and capable of completing all trial procedures\\[17\\]\n2. Age: 18 to 75 years old (including the cut-offs)\n3. Subjects must meet at least one of the following criteria for enrollment.\n\n 1. Patients diagnosed with chronic hepatitis B in hospital or out of hospital: persistent positive hepatitis B surface antigen (HBsAg) for 6 months or more\n 2. Patients diagnosed with hepatitis C in hospital or out of hospital\n 3. Patients diagnosed with cirrhosis in hospital or out of hospital who meet at least one of the following criteria.\n\n 1. Liver biopsy showing cirrhosis (Ishak score ≥5 or Metavir score = 4);\n 2. Liver stiffness measurement (LSM) using FibroScan® (Echosens™, Paris, France) ≥12.0 kPa when TB was normal and ALT ≤ 40 IU/mL, or LSM ≥ 17.0 kPa when TB was normal and ALT \\< 200 IU/mL;\n 3. Abdominal imaging results showing characteristic of cirrhosis (results showing coarse liver echotexture or nodular, parenchymal, or morphological abnormalities and signs of gastroesophageal varices);\n 4. APRI ≥ 2.0;\n 5. FIB-4 ≥ 3.25\n 4. Patients diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) in hospital or out of hospital who have a liver fibrosis score of F3 or higher according to transient elastography, i.e., FibroScan® Liver Stiffness Measurement (LSM) ≥ 10 kPa or the corresponding FibroTouch® measurement threshold\\[18\\].\n\n * MAFLD diagnosis requires diagnosis of \\>5% fat accumulation in liver through either FibroScan® CAP measurements, or similar parameter, or liver biopsy, and in combination with one of the following three conditions: overweight/obesity (BMI \\>23 kg/m2), type 2 diabetes, or metabolic dysfunction.\n 5. Patients diagnosed with MAFLD combined with abnormal glucose metabolism\\[19\\]\n\n * Abnormal glucose metabolism is defined as type 2 diabetes, or prediabetes, i.e. fasting blood glucose 5.6-6.9 mmol/L, or 2h postprandial blood glucose 7.8-11.0 mmol/L, or glycated hemoglobin 5.7%-6.4%\n 6. Subjects with a family history of liver cancer in their first-degree biological relatives.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded from the study:\n\n1. Age \\<18 years or \\>75 years\n2. Patients who have been diagnosed with liver cancer before enrollment\n3. Patients with severe mental illness or cognitive impairment\n4. Patients who are pregnant or lactating, or preparing to become pregnant\n5. Patients who have participated in other clinical trials or are participating in other clinical trials within 3 months prior to initiation of study treatment\n6. According to the doctor's judgment, the possibility of the subject being included is low (including inability to understand the project requirements , poor compliance, infirmity, inability to ensure that the protocol can be implemented as required, etc.), or the doctor determines that the subject has any other factors that are not suitable for this study"}, 'identificationModule': {'nctId': 'NCT05870969', 'acronym': 'dSEARCH', 'briefTitle': 'Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)', 'organization': {'class': 'OTHER', 'fullName': 'Ruijin Hospital'}, 'officialTitle': "Exploration of A Holistic Management Procedure for Liver Cancer Surveillance in Improving Liver Cancer's Early Diagnosis Efficacy in Chinese Population: Single-Center, Prospective, Observational Real-world Study in EASTERN China", 'orgStudyIdInfo': {'id': 'dSEARCH'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients with very high risk for HCC according local guideline', 'interventionNames': ['Behavioral: Liver cancer surveillance every 3 months']}, {'label': 'Patients with high risk for HCC according local guideline', 'interventionNames': ['Behavioral: Liver cancer surveillance every 3 months']}, {'label': 'Patients with medium risk for HCC according local guideline', 'interventionNames': ['Behavioral: Liver cancer surveillance every 6 months']}, {'label': 'Patients with low risk for HCC according local guideline', 'interventionNames': ['Behavioral: Liver cancer surveillance annually']}], 'interventions': [{'name': 'Liver cancer surveillance every 3 months', 'type': 'BEHAVIORAL', 'description': 'Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam', 'armGroupLabels': ['Patients with high risk for HCC according local guideline', 'Patients with very high risk for HCC according local guideline']}, {'name': 'Liver cancer surveillance every 6 months', 'type': 'BEHAVIORAL', 'description': 'Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam', 'armGroupLabels': ['Patients with medium risk for HCC according local guideline']}, {'name': 'Liver cancer surveillance annually', 'type': 'BEHAVIORAL', 'description': 'Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam', 'armGroupLabels': ['Patients with low risk for HCC according local guideline']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Qing Xie, MD, PhD.', 'role': 'CONTACT', 'email': 'xieqingrjh@163.com', 'phone': '0086-021-64370045', 'phoneExt': '680403'}, {'name': 'Honglian Gui, MD,PhD', 'role': 'CONTACT', 'email': 'lillian_ghl@163.com', 'phone': '0086-021-64370045', 'phoneExt': '680419'}, {'name': 'Qing Xie, MD, PhD.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'centralContacts': [{'name': 'Qing Xie, MD', 'role': 'CONTACT', 'email': 'xieqingrjh@163.com', 'phone': '0086-021-64370045', 'phoneExt': '680403'}, {'name': 'Honglian Gui, MD,PhD', 'role': 'CONTACT', 'email': 'lillian_ghl@163.com', 'phone': '0086-021-64370045', 'phoneExt': '680419'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Ruijin Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Director of Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine', 'investigatorFullName': 'Qing XIe', 'investigatorAffiliation': 'Ruijin Hospital'}}}}